A Phase 4 interventional study of Dapagliflozin 5 mg and Placebo tablet in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 14 sites in Japan. Open to participants aged 20 Years to 130 Years. Per ClinicalTrials.gov, last updated 2016-05-11.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 46th largest by enrollment, is one of 9 that started in 2014, is one of 77 in phase 4, and was the 48th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
Junjie Yang · Sites in China
Ages 18–78
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 53 · Phase 4 77
First in 2005; this study’s year is marked. 9 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 266 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 82 across the 180 interventional studies. Of the 136 that completed or were terminated, 68 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 180 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 109th largest by enrollment of the 280 interventional ones that give a count, is one of 17 that started in 2014, is one of 28 in phase 4, and was the 231st registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
6 of the studies testing dapagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311551Bhavya Bhavya, MDA Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI) | 2026-12 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07614230Junjie YangSGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes | 2027-06-01 |
| NCT07891234Sherihan AboElyazed Mohamed KhalilEffect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance | 2027-10-01 |
| NCT05938712University Health Network, TorontoThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
Japanese male and female patients with Type 2 Diabetes and aged ≥ 20 years old, with inadequate glycemic control on insulin defined as Haemoglobin A1c ≥ 7.2% and \< 11% will be enrolled into the wash-out phase or directly into the lead-in phase depending on whether the patient has been receiving an Oral antidiabetic drug (including Glucagon-Like Peptide-1 agonists and excluding Thiazolidinedions) other than a Dipeptidyl Peptidase-4 inhibitor as part of the baseline treatment. Additional treatment with a concomitant Dipeptidyl Peptidase-4 inhibitor is allowed. And around 180 eligible patients in total will be randomized into the study with a 2:1 randomization scheme (i.e.120 patients into the dapagliflozin treatment group and 60 patients into the placebo treatment group. All subjects who completed a 16 weeks double-blind treatment period will shift to a 36 weeks open extension treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
dapagliflozin tablet 5mg
Drug: Dapagliflozin 5 mg
dapagliflozin tablet 5mg placebo
Drug: Placebo tablet
Dapagliflozin, a blood glucose lowering drug. Oral dose
Placebo tablet. Oral dose
Adjusted Mean Change in HbA1c Levels
Mean change in HbA1c levels from baseline to Week 16 between dapagliflozin 5 mg versus placebo
Time frame: Baseline to Week 16
Fasting Plasma Glucose
Mean change in fasting plasma glucose from baseline to Week 16 between dapagliflozin 5 mg versus placebo
Time frame: Baseline to Week 16
Total Body Weight
Mean change in total body weight from baseline to Week 16 between dapagliflozin 5 mg versus placebo
Time frame: Baseline to Week 16
Total Mean Daily Insulin Dose
Mean change in calculated mean daily insulin dose from baseline to Week 16 between dapagliflozin 5 mg versus placebo
Time frame: Baseline to Week 16
Proportion of Participants With Mean Daily Insulin Dose Reduction of Greater Than or Equal 10%
Proportion of participants with mean daily insulin dose reduction greater than or equal 10% from baseline to week 16 (LOCF) between dapagliflozin 5 mg versus placebo
Time frame: Baseline to Week 16
First participant enrolled: 06-Jun-2014; Last participant last visit of ST period: 02-Feb-2015; 266 participants were enrolled in 20 Japanese centers. 183 Japanese men or women aged \>=20 years with inadequate glycemic control (HbA1c levels of \>=7.2% to \<11.0%) with diet, exercise and on stable dose of insulin +/- DPP-4 inhibitor were treated.
| Milestone | Dapagliflozin | Placebo |
|---|---|---|
| Started | 123 | 60 |
| Completed | 119 | 58 |
| Not completed | 4 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Subject no longer meets study criteria | 1 | 2 |
| Withdrew: Poor/non-compliance | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Mean change in HbA1c levels from baseline to Week 16 between dapagliflozin 5 mg versus placebo
| percentage of hemoglobin glycosylated | Dapagliflozin | Placebo |
|---|---|---|
| Adjusted Mean Change in HbA1c Levels | -0.55 (-0.67 to -0.42) | 0.05 (-0.13 to 0.23) |
Mean change in fasting plasma glucose from baseline to Week 16 between dapagliflozin 5 mg versus placebo
| mg/dL | Dapagliflozin | Placebo |
|---|---|---|
| Fasting Plasma Glucose | -21.7 (-28.3 to -15.1) | 1.0 (-8.4 to 10.3) |
Mean change in total body weight from baseline to Week 16 between dapagliflozin 5 mg versus placebo
| kg | Dapagliflozin | Placebo |
|---|---|---|
| Total Body Weight | -0.6 (-0.9 to -0.2) | 0.7 (0.2 to 1.1) |
Mean change in calculated mean daily insulin dose from baseline to Week 16 between dapagliflozin 5 mg versus placebo
| IU/Day | Dapagliflozin | Placebo |
|---|---|---|
| Total Mean Daily Insulin Dose | -0.74 (-1.21 to -0.27) | -0.02 (-0.68 to 0.64) |
Proportion of participants with mean daily insulin dose reduction greater than or equal 10% from baseline to week 16 (LOCF) between dapagliflozin 5 mg versus placebo
| percentage of participants | Dapagliflozin | Placebo |
|---|---|---|
| Proportion of Participants With Mean Daily Insulin Dose Reduction of Greater Than or Equal 10% | 8.2 (3.3 to 13.1) | 4.9 (-0.7 to 10.4) |
Collected over Non-serious/serious adverse events on or after the first date of double-blind treatment and on or prior to the last day plus 4/30 days or up to follow-up visit if earlier, or up to and excluding the start date of open-label extension period if earlier.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapagliflozin | — | 3/123 (2.4%) | 24/123 (19.5%) |
| Placebo | — | 0/60 (0%) | 10/60 (16.7%) |
| Event | Dapagliflozin | Placebo |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 1/123 | 0/60 |
| Hand fractureInjury, poisoning and procedural complications | 1/123 | 0/60 |
| OsteochondrosisMusculoskeletal and connective tissue disorders | 1/123 | 0/60 |
| Event | Dapagliflozin | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 13/123 | 7/60 |
| PollakiuriaRenal and urinary disorders | 11/123 | 3/60 |
| ConstipationGastrointestinal disorders | 3/123 | 3/60 |
The Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during the short-term double-blind treatment period.
| Age, Continuous(years) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| Mean | 58.3 ± 9.83 | 57.6 ± 9.86 | 58.0 ± 9.82 |
| Age, Customized(participants) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| <=65 years | 84 | 43 | 127 |
| Between 65 and 75 years | 37 | 16 | 53 |
| >=75 years | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| Female | 33 | 20 | 53 |
| Male | 89 | 40 | 129 |
| Region of Enrollment(participants) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| Japan | 122 | 60 | 182 |
| Body Weight(kg) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| Mean | 73.90 ± 15.663 | 71.89 ± 13.430 | 73.24 ± 14.956 |
| Body Mass Index(kg/m^2) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| Mean | 26.89 ± 4.930 | 26.12 ± 3.485 | 26.64 ± 4.510 |
| Waist Circumference(cm) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| Mean | 93.2 ± 11.83 | 92.3 ± 9.00 | 92.9 ± 10.96 |
| HbA1c(percent of hemoglobin glycosylated) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| Mean | 8.26 ± 0.792 | 8.52 ± 0.937 | 8.34 ± 0.849 |
3 further baseline measures are reported on the registry.
The record gives a start of Jun 2014, a primary completion of Feb 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin